Big Pharma’s Patents on Kratom Alkaloids

September 12, 2016

The DEA announced last week that Kratom would now be classified as a schedule 1 substance. In lamens terms, this means that it is as restricted as restricted gets, as schedule 1 controlled substances are considered to have no medicinal value whatsoever.

On August 31 a notice of intent to classify kratom was placed on the Federal Register. The intent stated plans to temporarily classify the supplement as a Schedule 1 substance on September 30. The notice reads:

Notice of Intent:

The Administrator of the Drug Enforcement Administration is issuing this notice of intent to temporarily schedule the opioids mitragynine and 7-hydroxymitragynine, which are the main active constituents of the plant kratom, into schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act.

This action is based on a finding by the Administrator that the placement of these opioids into schedule I of the Controlled Substances Act is necessary to avoid an imminent hazard to the public safety. Any final order will impose the administrative, civil, and criminal sanctions and regulatory controls applicable to schedule I controlled substances under the Controlled Substances Act on the manufacture, distribution, possession, importation, and exportation of, and research and conduct of instructional activities of these opioids.

The DEA states that kratom is to be considered an “imminent hazard” due to CDC reports stating that the substance can be abused and that over 660 calls have been received in 6 years regarding kratom intoxication. Compared to the number of overdose deaths, and complications caused by opiates, one might think that this number isn’t quite so terrible. On top of that, there is no link to kratom actually being found to be deadly at all. However, Tylenol has been referred to as the number one reason for CDC calls each year…..

What we have here is another case of the DEA banning a beneficial plant to help protect big pharma. Think about it….Cannabis is a schedule 1 substance, but as soon as big pharma created a synthetic version of THC, suddenly, well, that’s ok.

And it is the same with kratom, as the pharmaceutical industry has been using kratom alkaloids to create synthetic opioids.

As Cassius Kamarampi points out, three synthetic opioids, in particular, were synthesized from the alkaloids in kratom from 2008- 2016: MGM-9, MGM-15, and MGM-16.

They were synthesized from kratom’s alkaloids Mitragynine and 7-Hydroxymitragynine: to make what is essentially patentable, pharmaceutical kratom.

The first study, published in 2008, took Mitragynine and used it to synthesize “MGM-9”.

The study says:

“Mitragynine is a major indole alkaloid isolated from the Thai medicinal plant Mitragyna species that has opium-like properties, although its chemical structure is quite different from that of morphine. We attempted to develop novel analgesics derived from mitragynine, and thus synthesized the ethylene glycol-bridged and C10-fluorinated derivative of mitragynine, MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate].”

The second study published in 2014 synthesized MGM-15 and MGM-16 from kratom’s other primary alkaloid, 7-Hydroxymitragynine. The study says:

“In this study, we developed dual-acting μ- and δ-opioid agonists MGM-15 and MGM-16 from 7-hydroxymitragynine for the treatment of acute and chronic pain.”

And it doesn’t stop there either. There are dozens upon dozens of studies within just the last few years that included researchers synthesizing new opioid compounds, and then testing them on primates.

Read More

0 comment